昭衍新藥(06127.HK)共斥逾18億人幣全購收購兩家實驗室實驗模型銷售商
昭衍新藥(06127.HK)公佈,向英茂集團收購英茂生物科技全部股權,代價爲8.3億元人民幣(下同)。另以總代價9.74億元向官房集團及協爾雲康分別購買瑋美生物科技的60%及40%股本權益。
英茂生物科技及瑋美生物科技同爲公司供應商,且主要業務均爲繁育和銷售實驗室實驗模型。
公司認爲,收購事項可讓集團滿足業務規模進一步擴展的需要,以及提升集團合同研究組織服務的能力。此外,收購事項可透過上遊垂直整合爲集團的業務帶來協同效應,降低實驗模型供應中斷可能帶來的風險及任何負面影響,以及基於實驗室實驗模型的價格呈上升趨勢,收購可達致更佳的成本控制。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.